1. Home
  2. RPD vs ABUS Comparison

RPD vs ABUS Comparison

Compare RPD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

HOLD

Current Price

$6.23

Market Cap

780.5M

Sector

Technology

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.58

Market Cap

888.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPD
ABUS
Founded
2000
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
780.5M
888.5M
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
RPD
ABUS
Price
$6.23
$4.58
Analyst Decision
Hold
Strong Buy
Analyst Count
21
1
Target Price
$16.15
$5.00
AVG Volume (30 Days)
1.9M
1.8M
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
13.64
EPS
0.36
N/A
Revenue
$685,083,000.00
$6,171,000.00
Revenue This Year
N/A
$125.30
Revenue Next Year
$0.93
N/A
P/E Ratio
$17.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.92
$2.71
52 Week High
$30.95
$5.10

Technical Indicators

Market Signals
Indicator
RPD
ABUS
Relative Strength Index (RSI) 15.03 60.77
Support Level N/A $4.22
Resistance Level $19.70 $4.69
Average True Range (ATR) 0.58 0.24
MACD -0.16 0.07
Stochastic Oscillator 5.33 88.32

Price Performance

Historical Comparison
RPD
ABUS

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: